A matrine-type alkaloid and its preparation method and use in preparing drugs with anti-neuroinflammatory effects

By isolating and developing a completely new structure of malphinol-type alkaloid from sophora glutinosa, the problem of difficult to detect small molecule compounds that inhibit microglia activation in the prior art is solved, and excellent anti-neuroinflammatory effects and comparison are achieved. Low toxic drug ingredients have potential application value in the treatment of neurodegenerative diseases.

CN116535416BInactive Publication Date: 2024-11-29THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211095031.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-05
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

It is difficult to discover or develop small molecule compounds that can effectively inhibit the activation of microglia and their expression of inflammatory factors in cells, and are then used to treat neuroinflammation and its neurodegenerative diseases.

Method used

Isolated and developed a completely new structure of malphinol-type alkaloid from Sophora, which has the structure of formula I, formula II or formula III, as a potential drug through excellent anti-neuroinflammatory effects and low toxicity Ingredients are used to prepare drugs with anti-neuroinflammatory effects.

Benefits of technology

This malpine-type alkaloid showed excellent anti-neuroinflammatory effects in the experiment, could inhibit the activation of microglia and the release of inflammatory factor NO, and had no significant impact on cell survival and had low toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116535416B_ABST
    Figure CN116535416B_ABST
Patent Text Reader

Abstract

The present invention specifically discloses a matrine-type alkaloid, a preparation method thereof, and an application thereof in the preparation of a drug having an anti-neuroinflammatory effect. The matrine-type alkaloid has a structure shown in Formula I, Formula II, or Formula III. The composition and extract contain any one or more matrine-type alkaloids having a structure shown in Formula I, Formula II, or Formula III. Studies have shown that the matrine-type alkaloids having a structure shown in Formula I, Formula II, or Formula III of the present invention have excellent anti-neuroinflammatory effects; in particular, they also have low toxicity. Therefore, using a matrine-type alkaloid having a structure shown in Formula I, Formula II, or Formula III, or a composition or extract containing a matrine-type alkaloid having a structure shown in Formula I, Formula II, or Formula III as an active ingredient for the preparation of a drug having an anti-neuroinflammatory effect has important application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical chemistry, and in particular to a matrine-type alkaloid, a preparation method thereof, and an application thereof in the preparation of a drug with anti-neuroinflammatory effect. Background Art

[0002] As the aging of my country's population accelerates, neurodegenerative diseases have received more and more attention. Studies in recent years have shown that neuroinflammation is one of the important causes of many neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), and the activation of microglia is critical in the occurrence and development of neuroinflammation. Therefore, if small molecule compounds can be found to inhibit microglial activation and the expression of inflammatory factors in their cells, they may be potentially used to treat neuroinflammation and the many neurodegenerative diseases it causes.

[0003] Discovering bioactive compound molecules from traditional Chinese medicine has always been an important means of drug discovery. Sophora flavescens (Latin name: Sophora flavescens) is a plant of the genus Sophora in the family Fabaceae. It has been used as a traditional Chinese medicine in my country for thousands of years. Matrine-type alkaloids, the main components of Sophora flavescens, have clinical effects of clearing heat and dampness, and anti-inflammatory. Modern pharmacological research results also show that matrine-type alkaloids have different degrees of anti-inflammatory activity. Since there are few reports on whether matrine-type alkaloids have the activity of inhibiting neuroinflammation, it is of great application value to develop matrine-type alkaloids with anti-neuroinflammatory activity from Sophora flavescens. Summary of the invention

[0004] In order to overcome the above-mentioned technical problems existing in the prior art, the present invention provides a new matrine-type alkaloid; studies have shown that the matrine-type alkaloid with a new structure of the present invention has excellent anti-neuroinflammatory effects.

[0005] The technical solution of the present invention is as follows:

[0006] The present invention first provides a matrine-type alkaloid having a structure shown in Formula I, Formula II or Formula III:

[0007]

[0008] The present invention has found in the research that the matrine-type alkaloids having the structure shown in Formula I, Formula II or Formula III have excellent anti-neuroinflammatory effects. In particular, the matrine-type alkaloids having the structure shown in Formula I, Formula II or Formula III have no significant effect on cell survival rate during the experiment and have low toxicity to cells.

[0009] The present invention also provides a composition comprising any one or more matrine-type alkaloids having structures represented by formula I, formula II or formula III.

[0010] The present invention also provides an extract, which contains any one or more matrine-type alkaloids having structures shown in formula I, formula II or formula III.

[0011] Preferably, the extract comprises matrine-type alkaloids having structures shown in Formula I, Formula II and Formula III.

[0012] Preferably, the total weight of the matrine-type alkaloids having structures represented by formula I, formula II and formula III accounts for more than 10% of the total weight of the extract.

[0013] More preferably, the total weight of the matrine-type alkaloids having structures represented by Formula I, Formula II and Formula III accounts for 20% to 80% of the total weight of the extract.

[0014] Preferably, the extract is Sophora flavescens extract.

[0015] The present invention also provides a use of the above-mentioned matrine-type alkaloids, compositions or extracts in the preparation of drugs with anti-neuroinflammatory effects.

[0016] Preferably, the matrine-type alkaloid, composition or extract is used in the preparation of a treatment for a neurodegenerative disease caused by neuroinflammation.

[0017] Preferably, the neurodegenerative diseases include Alzheimer's disease and Parkinson's disease.

[0018] Preferably, the drug is prepared into powder, pill, tablet, capsule, oral solution, aerosol or injection.

[0019] Beneficial effects: The present invention provides a matrine-type alkaloid with a completely new structure; studies have shown that the matrine-type alkaloid with a structure shown in Formula I, Formula II or Formula III of the present invention has excellent anti-neuroinflammatory effects; in particular, it also has low toxicity. Therefore, using the matrine-type alkaloid with a structure shown in Formula I, Formula II or Formula III, or a composition or extract containing the matrine-type alkaloid with a structure shown in Formula I, Formula II or Formula III as an active ingredient for preparing a drug with anti-neuroinflammatory effects has important application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is the single crystal structure diagram of the compound Sophflarine F.

[0021] Figure 2 This is the single crystal structure diagram of the compound Sophflarine G.

[0022] Figure 3 This is the single crystal structure diagram of the compound Sophflarine H.

[0023] Figure 4 This is the high-resolution mass spectrum of the compound Sophflarine F.

[0024] Figure 5 This is the hydrogen spectrum of compound Sophflarine F (600M, CDCl3).

[0025] Figure 6 This is the carbon spectrum of compound Sophflarine F (150M, CDCl3).

[0026] Figure 7 This is the DEPT spectrum of compound Sophflarine F (150M, CDCl3).

[0027] Figure 8 Sophflarine F 1 H- 1 H COSY spectrum.

[0028] Fig. 9 This is the HSQC spectrum of compound Sophflarine F.

[0029] Fig.10 This is the HMBC spectrum of compound Sophflarine F.

[0030] Fig.11 This is the high-resolution mass spectrum of the compound Sophflarine G.

[0031] Fig.12 This is the hydrogen spectrum of compound Sophflarine G (600M, CDCl3).

[0032] Fig.13 This is the carbon spectrum of compound Sophflarine G (150M, CDCl3).

[0033] Fig.14 This is the DEPT spectrum of compound Sophflarine G (150M, CDCl3).

[0034] Fig.15 Sophflarine G 1 H- 1 H COSY spectrum.

[0035] Fig.16 This is the HSQC spectrum of compound Sophflarine G.

[0036] Fig.17 This is the HMBC spectrum of compound Sophflarine G.

[0037] Fig.18 This is the high-resolution mass spectrum of the compound Sophflarine H.

[0038] Fig.19 This is the hydrogen spectrum of compound Sophflarine H (600M, CDCl3).

[0039] Fig. 20 This is the carbon spectrum of compound Sophflarine H (150M, CDCl3).

[0040] Fig.21 This is the DEPT spectrum of compound Sophflarine H (150M, CDCl3).

[0041] Fig. 22 For the compound Sophflarine H 1 H- 1 H COSY spectrum.

[0042] Fig.23 This is the HSQC spectrum of compound Sophflarine H.

[0043] Fig.24 This is the HMBC spectrum of compound Sophflarine H.

[0044] Fig.25 This is a diagram showing the pharmacological experimental results of sophflarine F, sophflarine G, and sophflarine H.

[0045] Fig.26 A numbered diagram of the structure of sophflarine F.

[0046] Fig. 27 A numbered diagram of the structure of sophflarine G.

[0047] Fig.28 Numbered diagram of the structure of sophflarine H. DETAILED DESCRIPTION

[0048] The present invention is further explained below in conjunction with specific examples, but the examples do not limit the present invention in any form.

[0049] Example 1 Preparation of matrine-type alkaloids

[0050] (1) 30 kg of dried root of Sophora flavescens was taken, 5 times the amount of 95% (v / v) ethanol was added, and the mixture was subjected to heat reflux extraction for 2 times, and the mixture was filtered, and the solvent was recovered by decompressing the filtrate to obtain 2000 g of total extract; the total extract was suspended in water, the pH was adjusted to 3 with 1% HCl, the mixture was stirred, and the mixture was allowed to stand for 2 hours, and the mixture was extracted with chloroform to remove impurities, and the acidic water layer after the impurities were removed was adjusted to pH 10 with 2% ammonia water, the mixture was stirred, and the mixture was allowed to stand for 2 hours, and the chloroform extract was re-extracted, and the chloroform extract was concentrated under reduced pressure to obtain 800 g of total alkali;

[0051] (2) The total alkali was suspended with 30% ethanol by volume, applied to a D101 macroporous resin column, and then gradient eluted with 30%, 50%, 70% and 95% ethanol in sequence to obtain four fractions, which were named macroporous resin column fraction 1 to fraction 4;

[0052] (3) The macroporous resin column fraction 1 was further subjected to silica gel column chromatography, and gradient elution was performed with a dichloromethane-methanol system (90:10, 80:20, 70:30, 50:50, v:v) in sequence, and four fractions were obtained based on each gradient ratio, and were named silica gel column fraction 1 to fraction 4;

[0053] (4) The silica gel column fraction 2 was further subjected to ODS reverse phase column chromatography, and gradient elution was performed with a methanol-water system (10:90, 20:80, 30:70, 50:50, v:v) in sequence, and four fractions were obtained based on each gradient ratio, which were named ODS column fraction 1 to fraction 4;

[0054] (5) The ODS column fraction three was separated by preparative high performance liquid chromatography (using a C18 reverse phase column) to obtain matrine-type alkaloids of structures represented by formula I, formula II and formula III; the matrine-type alkaloid of the structure represented by formula I was named sophflarine F; the matrine-type alkaloid of the structure represented by formula II was named sophflarine G; the matrine-type alkaloid of the structure represented by formula III was named sophflarine H;

[0055] Among them, the conditions of preparative high performance liquid chromatography are acetonitrile: water = 90:10, flow rate 6 ml / min, detection wavelength 254 nm, collecting the chromatographic peak with a retention time of 60.1 min to obtain compound sophflarine F; collecting the chromatographic peak with a retention time of 71.1 min to obtain compound sophflarine G; collecting the chromatographic peak with a retention time of 80.3 min to obtain compound sophflarine H.

[0056] Structural identification of sophflarine F, G, and H:

[0057] The isolated compounds sophflarine F, sophflarine G, and sophflarine H are all colorless block crystals with specific rotations of UV spectrum shows that the maximum absorption is around 205nm. Combined with the ultraviolet absorption characteristics of matrine structure, it can be deduced that there is only amide bond functional group; high-resolution mass spectrometry combined with carbon spectrum shows that the first two compounds have the same molecular formula, which is C 15 H 22 N2O3 has one more oxygen atom unit, which is C 15 H 22 For N2O4, the calculated value of unsaturation is 6.

[0058] Compound sophflarine F 13 C NMR combined with DEPT spectrum shows that the 15 carbon signals are 1 amide carbonyl (δ C 172.0), a methine (δ C 56.7), 10 methylene groups (δ C 47.5×2,47.1,30.8,27.5,25.6,22.1,19.8,19.1,16.8), and three oxygen-linked quaternary carbon signals (δ C 84.0,83.9,81.8); the above data combined 1 The typical C-17 signal [δ C 47.5,δ Hα 3.68 (d, J = 13.0 Hz); δ Hβ 3.40 (d, J = 13.0 Hz)], which is obtained by replacing the C-5 position of matrine with a hydroxyl group. The above 1D NMR information combined with the remaining 5 unsaturations indicate that compound sophflarine F is a new type of pentacyclic matrine alkaloid. HMBC long-range correlations from H2-17 to C-5 / C-6, from H-11 to C-6 / C-7, and from H2-2 / H2-10 to C-6 determined that C-5 / C-6 / C-7 are oxygen-linked sites; finally, the planar structure of sophflarine F was determined to be a novel 6 / 6 / 6 / 6 / 4 pentacyclic matrine alkaloid using X-Ray single crystal diffraction, and the structural formula is shown in Formula I.

[0059] Compound sophflarine G 1 H NMR spectra and 13The C NMR spectrum data is similar to that of sophflarine F. Combined with the HSQC spectrum, it can be seen that there are only slight differences in chemical shifts, which are mainly reflected in the carbon-hydrogen sites of H2-2 / H2-10 / H2-17 and C-11. After the two-dimensional correlation was used to assign all carbon and hydrogen, it was determined that the two had the same planar structure; finally, the X-Ray single crystal diffraction method verified that the compound sophflarine G is a novel 6 / 6 / 6 / 6 / 4 pentacyclic system matrine-type alkaloid, and the structural formula is shown in Formula II.

[0060] The NMR data of compound sophflarine H are similar to those of sophflarine F, except that the methylene group (δ C 31.3) is connected to an oxygen-linked methyl group (δ C 68.6), combined with the fact that the molecular formula of sophflarine H is 16 more mass units than that of sophflarine F, and the two groups of HMBC related peaks from H2-12 to C-14 and from H-14 to C-12 / C-15 in sophflarine H, it can be inferred that sophflarine H is a hydroxyl-substituted derivative of sophflarine F at the C-14 position. Finally, the X-Ray single crystal diffraction method also verified that the compound sophflarine G is a novel 6 / 6 / 6 / 6 / 4 pentacyclic system matrine-type alkaloid, and the structural formula is shown in Formula III.

[0061] Table 1. Hydrogen and carbon spectra of compound sophflarine FH (CDCl3, δ in ppm, J in Hz) a

[0062]

[0063] a Note: Overlapping peaks were not assigned for multiple peak analysis.

[0064] The physicochemical properties of the compound sophflarine FH are as follows:

[0065] Sophflarine F: colorless blocky crystals; mp 138–139°C; specific rotation [α] 25 D -16.8(c 0.10,CH3OH); UV(CH3OH)λ max (logε)206(3.24)nm; 1 H NMR (600 MHz, CDCl3) and 13C NMR (150MHz, CDCl3), see Table 1; High resolution mass spectrum HRESIMS m / z 279.1693 [M+H] + (Calculated value C 15 H 23 N2O3,279.1703).

[0066] Sophflarine G: colorless blocky crystals; mp 140–141°C; specific rotation [α] 25 D +29.6(c 0.10,CH3OH); UV(CH3OH)λ max (logε)205(3.23)nm; 1 H NMR (600 MHz, CDCl3) and 13 C NMR (150MHz, CDCl3), see Table 1; High resolution mass spectrum HRESIMS m / z 279.1704 [M+H] + (Calculated value C 15 H 23 N2O3,279.1703).

[0067] Sophflarine H: colorless blocky crystals; mp 146–147°C; specific rotation [α] 25 D +21.0(c 0.10,CH3OH); UV(CH3OH)λ max (logε)206(3.02)nm; 1 H NMR (600 MHz, CDCl3) and 13 C NMR (150MHz, CDCl3), see Table 1; High resolution mass spectrum HRESIMS m / z 295.1642 [M+H] + (Calculated value C 15 H 23 N2O4,295.1652).

[0068] Experimental example

[0069] (1) Cell viability assay:

[0070] a. The culture method of mouse microglial BV-2 cell line is the same as described in the literature [Journal of Natural Products, 2021, 84(7): 1898-1903].

[0071] b. Prepare MTT working solution: Weigh 0.5 g MTT using an electronic balance and dissolve it in 100 mL phosphate buffer (PBS) to a final concentration of 5 mg / mL MTT. Filter through a 0.22 μm filter and aliquot, store at -20°C away from light.

[0072] c. When the cell density reaches 80-90%, trypsinize the cells and adjust the concentration of the cell suspension so that each 100 μl of cell suspension contains 5,000 cells. Plate a 96-well plate with 100 μl of cell suspension in each well. Cultivate in a 37°C, 5% CO2 cell culture incubator until the cells are completely attached to the wall. Then add different concentrations of matrine-type alkaloids (sophflarine F, sophflarine G, sophflarine H) for 24h, 48h and 72h, respectively. Add an equal volume of PBS to the control group, and set up 6 replicate wells for each treatment group.

[0073] d. After the matrine-type alkaloids were exposed to the set time, the culture medium in the wells was removed, the cells in the wells were washed twice with PBS, and 20 μl of MTT solution was added to each well, and the cells were cultured for another 4 h.

[0074] e. Terminate the culture after 4 hours, remove the culture medium from the wells, add 150 μl of DMSO solution to each well, wrap the 96-well plate with tin foil to protect it from light, and incubate on a shaker for 10 minutes to allow the crystals to fully dissolve.

[0075] f. Use a multifunctional microplate reader to detect the absorbance value of each well at OD 570nm.

[0076] (2) NO release inhibition experiment in BV-2 cells: The NO generation concentration in the culture medium was determined according to the method provided in the instructions of the commercially available detection kit. After incubation with 50 μL of Griess reagent (0.1% N-1-naphthylethylenediamine dihydrochloride, 1% sulfonamide) and an equal volume of culture cell supernatant, the absorbance (540 nm) was measured on a microplate. Based on the inhibition rate of 4 concentrations (6.25-100 μM), the IC of each test compound was calculated using nonlinear regression analysis. 50 The experiments at the same concentration were repeated 3 times.

[0077] Pharmacological experiment results:

[0078] The occurrence of neurodegenerative diseases originates from a variety of neuroinflammatory reactions. In the state of neuroinflammation, microglia (BV-2) are overactivated, inducing nitric oxide synthase (iNOS) to overexpress nitric oxide (NO). Fig.25As shown, the new alkaloids sophflarine F, sophflarine G, and sophflarine H isolated from Sophora flavescens have no significant effect on the cell survival rate of BV-2 cells at a high concentration of 100 μM, but can dose-dependently inhibit the release of NO produced by BV-2 cells overexpressed after LPS induction in the concentration range of 6.25-100 μM, and there is a significant difference in the NO release amount compared with the LPS group without administration and the blank group. The positive control used in this experiment, dexamethasone (Dexamethasone, referred to as DEX), has an inhibition rate of 42.5% at a concentration of 10 μM on the release of NO produced by BV-2 cells overexpressed after LPS induction, which indicates that the compound of the present invention exhibits an activity equivalent to that of the positive control at a concentration of 25 μM, and can exhibit a better inhibitory effect on the neuroinflammatory factor NO than the positive control at a high concentration. The above results comprehensively show that the matrine-type alkaloids of the structures shown in Formula I, Formula II, and Formula III have anti-neuroinflammatory effects and can be used as potential neuroinflammatory inhibitors for the treatment of neurodegenerative diseases.

Claims

1. A matrine-type alkaloid, characterized in that: It has a structure shown in Formula I, Formula II or Formula III: Formula I; Formula II; Formula III.

2. Use of the matrine-type alkaloids according to claim 1 in the preparation of drugs having anti-neuroinflammatory effects.

3. The use according to claim 2, characterized in that: The application of the matrine-type alkaloids in the preparation of neurodegenerative diseases caused by neuroinflammation.

4. The use according to claim 3, characterized in that: The neurodegenerative diseases include Alzheimer's disease and Parkinson's disease.

5. The use according to claim 2, characterized in that: The medicine is prepared into powder, pill, tablet, capsule, oral liquid, aerosol or injection.

Citation Information

Patent Citations

  • Sophocarpidine alkaloid as well as preparation method and application thereof

    CN112300163A

  • Active alkaloid compound, radix sophorae flavescentis extract and application of active alkaloid compound and radix sophorae flavescentis extract in preparation of product with skin itch resisting effect

    CN114539259A